Skip to content

Search for Restenosis Markers in Lower Limb Arteritis

Search for Restenosis Markers in Lower Limb Arteritis

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03146221
Acronym
FEMIA
Enrollment
0
Registered
2017-05-09
Start date
2017-06-20
Completion date
2020-06-20
Last updated
2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Limb Arteritis, Restenosis

Brief summary

The initial hypothesis of this work is that the genesis and the evolution of the atheromatous plaque are partly controlled at the molecular level and in particular by the microRNAs through their role as regulator of the genes. The study of the tissue and serum profile over time of specific microRNAs involved in the regulation of atheromatous plaque correlated with clinical data and restenosis imaging will allow to define biological markers of restenosis in the patient with an arteritis of the lower limbs . This study is a pioneer in the field and it would be imprudent to conclude that a biomarker would be used clinically at the end of this work alone. Nevertheless this study will make a major advance in this topic, in vivo intervention studies with inhibition or over-expression of microRNA will obviously be necessary to confirm the use of these as biomarkers of arteritis of the lower limbs. Regular assay of reliable biomarkers in arterial patients will ultimately suggest early management to best adapt surgical and medical treatment.

Interventions

OTHERTo look for serum microRNA profiles associated with restenosis

To look for serum microRNA profiles associated with restenosis

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Any person to be surgically treated for arteritis on the femoropoplitetic stage, * affiliated to a social security scheme, * informed of the study and not opposed to it.

Exclusion criteria

* Any person taken in charge for an arteritis on the femoro-popliteal floor refusing to participate in the study, * or not being able to express its consent.

Design outcomes

Primary

MeasureTime frame
Study of the tissue and serum profile of microRNAs by quantification by real-time PCR3 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026